Long term extension study for gotistobart treated patients
Part of Cancer clinical trials.
This study is for people who have already been taking the drug gotistobart in a previous trial. It allows them to keep receiving the drug for a longer time, so doctors can see how the treatment works over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and agree to take part in the study.
- You have been diagnosed with advanced solid tumor cancer that cannot be removed by surgery or has spread.
- You are currently in a qualifying study called PRESERVE-100 and are being treated with gotistobart, either alone or with other drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This is an early-stage study testing a new drug called GTB-5550 in people with advanced cancers that have spread. The study aims to find the right dose and see if the drug helps shrink tumors.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
This trial tests a drug called Benmelstobart for people with locally advanced stomach or gastroesophageal junction cancer that can be removed with surgery. The goal is to see if it is safe and effective.
This trial tests whether adding a new drug called SYS6006 to an existing cancer treatment (enlonstobart) works better than enlonstobart alone for advanced solid tumors that cannot be surgically removed. The goal is to see if the combination helps shrink tumors and improve survival.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.